Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for treating pituitary adenoma, application of medicine composition, medicine box and packaging piece

A technology of pituitary adenoma and composition, applied in the field of biomedicine

Active Publication Date: 2015-09-23
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] So far, there have been no reports about the induction of autophagy in pituitary adenoma cells by dopamine receptor agonists (especially cabergoline) and the combined application of chloroquine to enhance the therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating pituitary adenoma, application of medicine composition, medicine box and packaging piece
  • Medicine composition for treating pituitary adenoma, application of medicine composition, medicine box and packaging piece
  • Medicine composition for treating pituitary adenoma, application of medicine composition, medicine box and packaging piece

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1, Cabergoline-induced autophagy in rat MMQ and GH3 cells

[0033] Experimental Materials:

[0034] Rat pituitary tumor cell line MMQ (ATCC) at 37 °C, 5 % CO 2 Under normal conditions, the culture medium was DMEM / F12 (Gibco) containing 2.5% fetal bovine serum (Gibco) plus 12.5% ​​horse serum; cabergoline was purchased from Tocris (UK), and the mother solution 100mM was prepared by DMSO; GFP-LC3 Plasmids were from Addgene. Chloroquine (CQ) was purchased from sigma (USA), and the mother solution was prepared with 100 mM ultrapure water; MTS and ATP detection cell viability reagents were purchased from Promega (USA); RIPA lysate and PMSF were purchased from Beyond Biotechnology Research Institute (Jiangsu) ; Protease Inhibitor Cocktail was purchased from Merck (Germany).

[0035] experimental method:

[0036] 1) Cell culture and administration

[0037] Cells were suspended in regular culture medium and the cell density was adjusted to 1×10 6 Cells / ...

Embodiment 2

[0059] Example 2, Cabergoline inhibits mTOR signaling pathway experiment

[0060] Experimental material: with embodiment 1.

[0061] Western Blot detection of expression of Polyclonal anti-phospho-AKT, anti-AKT, anti-phospho-p70s6k, anti-p70s6k, anti-phospho-4EBP1, anti-4EBP1, anti-phospho-mTOR, and anti-mTOR;

[0062] The experimental method is the same as the protein detection method in the implementation case 1, figure 2 Selected representative experimental results are shown, and the results show that cabergoline has an inhibitory effect on the mTOR pathway on MMQ cells.

Embodiment 3

[0063] Example 3, In Vitro Test of Chloroquine Combined with Cabergoline

[0064] 1. MMQ cell MTS assay to detect the efficacy of CAB+CQ (such as image 3 As shown in A)

[0065] 1) Suspend the cells in regular culture medium and adjust the cell density to 1×10 4 The cells / well were inoculated in a 96-well culture plate, and the drug-containing medium was added to divide into 4 groups, namely DMSO, CAB, CQ and CAB+CQ groups, with 5 secondary wells in each group, so that the final concentration of cabergoline was 50 μM. The final concentration of CQ was 20uM, and the blank control group contained 0.3% DMSO;

[0066] 2) Culture the administered cells for 24 hours at 37 °C, 5% CO2;

[0067] 3) Add 20 μl MTS solution to each well, and continue culturing in the incubator for 4 hours;

[0068] 4) Measure the absorbance value with a detection wavelength of 490nm, calculate the growth inhibition rate of the cells, N=5, and run the experiment in parallel three times;

[0069] 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicine and relates to a medicine composition for treating pituitary adenoma, application of the medicine composition, a medicine box and a packaging piece. The medicine composition, the medicine box and the packaging piece contain chloroquine / hydroxychloroquine which serves as a combined preparation and is used simultaneously, separately or sequentially, and a therapeutically effective amount of dopamine receptor agonist, and the dopamine receptor agonist is cabergoline or bromocriptine. When the medicine composition, the medicine box and the packaging piece are used for treating tumors, the medicine effect which is superior to the medicine effect obtained by separately using the cabergoline can be achieved, and the clinical treatment effect is improved.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a pharmaceutical composition for treating pituitary adenoma, an application thereof, a medicine box and a package. Background technique [0002] According to reports, the annual incidence of pituitary adenoma is as high as 7.5-15 / 100,000 people, and the detection rate of pituitary adenoma in random MRI examination of normal population is 10%-38.5% (average 22.5%). According to the current statistics of my country's existing population of 1.3 billion, the annual number of new cases of pituitary adenoma reaches nearly 200,000. Pituitary prolactinoma (prolactinoma) is the most common functional pituitary adenoma, accounting for about 40% to 60% of all pituitary adenomas. Based on the above data, the annual number of new cases of prolactinoma is about 80,000 to 120,000. In fact, with the continuous advancement of endocrine diagnostic techniques, neuroimaging equipme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/4706A61K31/4709A61K31/48A61P35/00A61P5/00
Inventor 吴哲褒林绍坚冷志根赵卫国
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com